Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa

Go back to Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa
(NASDAQ: KRYS) Delayed: 345.55 -2.54 (0.73%)
Previous Close $348.09    52 Week High
Open $347.56    52 Week Low
Day High $349.66    P/E N/A 
Day Low $344.26    EPS
Volume 175,553